NeoGenomics, Inc. Hits New 52-Week High at $14.79

NeoGenomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 14.79 on June 30, 2026. This achievement marks a notable increase from its 52-week low of USD 4.72, reflecting a year-over-year performance of 9.53%. Despite this upward movement, NeoGenomics' performance has lagged behind the S&P 500, which has seen a gain of 20.86% over the same period. The company currently holds a market capitalization of USD 933 million, and its financial metrics indicate a debt-to-equity ratio of 0.22. However, it is important to note that NeoGenomics is currently operating at a loss, as indicated by its negative return on equity of -8.39%. With no dividend yield and a price-to-book ratio of 1.12, NeoGenomics continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry while achieving this notable price milestone.